Pierre Geborek

knuten till universitetet
Fler filtreringsmöjligheter
  1. 2020
  2. 2019
  3. 2018
  4. 2017
  5. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry

    Tanja Schjødt Jørgensen, Carl Turesson, Meliha Kapetanovic, Martin Englund, Aleksandra Turkiewicz, Robin Christensen, Henning Bliddal, Pierre Geborek & Lars Erik Kristensen, 2017 feb 1, I : PLoS ONE. 12, 2, 0169946.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.

    Johanna Nagel, Pierre Geborek, Anders Bengtsson, S Jacobsen, Svaerke Joergensen C, Jan-Åke Nilsson, Lillemor Melander Skattum, Andreas Jönsen & Meliha C Kapetanovic, 2017 jan 1, I : Lupus. 1, s. 1-10 10 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  7. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: Does early anti-TNF therapy bring patients back to work?

    Tor Olofsson, I. F. Petersson, J. K. Eriksson, M. Englund, Jan-Åke Nilsson, P. Geborek, L. T H Jacobsson, ARTIS Study Group ARTIS Study Group, J Askling & M Neovius, 2017, I : Annals of the Rheumatic Diseases. 76, 7, s. 1245-1252

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  8. Treatment with belimumab in SLE does not alter antobody response to 13-valent pneumococcal vaccine

    Johanna Nagel, Tore Saxne, Pierre Geborek, Anders Bengtsson, S Jacobsen, Svaerke Joergensen C, Jan-Åke Nilsson, Lillemor Skattum, Andreas Jönsen & Meliha C Kapetanovic, 2017, I : Lupus. 26, 10, s. 1072-1081

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  9. 2016
  10. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden

    JOHAN KARLSSON WALLMAN, Jonas K. Eriksson, Jan Åke Nilsson, Tor Olofsson, Lars Erik Kristensen, Martin Neovius & Pierre Geborek, 2016 jul 1, I : Journal of Rheumatology. 43, 7, s. 1292-1299 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  11. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.

    Alf Kastbom, Kristina Forslind, Sofia Ernestam, Pierre Geborek, Johan Karlsson, Ingemar Petersson, Saedis Saevarsdottir, Lars Klareskog, Ronald F van Vollenhoven & Karin Lundberg, 2016, I : Annals of the Rheumatic Diseases. 75, 2, s. 356-361

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  12. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

    Lars Erik Kristensen, Elisabeth Lie, Lennart Jacobsson, Robin Christensen, Philip J Mease, Henning Bliddal & Pierre Geborek, 2016, I : Journal of Rheumatology. 43, 1, s. 81-87

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. 2015
  14. Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

    Ronald F van Vollenhoven, Rebecca Bolce, Karen Hambardzumyan, Saedis Saevarsdottir, Kristina Forslind, Ingemar Petersson, Eric H Sasso, C C Hwang, Oscar G Segurado & Pierre Geborek, 2015, I : Arthritis & Rheumatology. 67, 11, s. 2855-2860

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  15. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.

    Jonas Eriksson, Johan Karlsson, Johan Bratt, Ingemar Petersson, Ronald van Vollenhoven, Sofia Ernestam, Pierre Geborek & Martin Neovius, 2015, I : Annals of the Rheumatic Diseases. 74, 6, s. 1094-1101

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  16. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial

    Saedis Saevarsdottir, Hamed Rezaei, Pierre Geborek, Ingemar Petersson, Sofia Ernestam, Kristina Albertsson, Kristina Forslind & Ronald F. van Vollenhoven, 2015, I : Annals of the Rheumatic Diseases. 74, 8, s. 1509-1514

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  17. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

    Karen Hambardzumyan, Rebecca Bolce, Saedis Saevarsdottir, Scott E Cruickshank, Eric H Sasso, David Chernoff, Kristina Forslind, Ingemar Petersson, Pierre Geborek & Ronald F van Vollenhoven, 2015, I : Annals of the Rheumatic Diseases. 74, 6, s. 1102-1109

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  18. 2014
  19. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

    Irini Flouri, Theodora E. Markatseli, Paraskevi V. Voulgari, Kyriaki A. Boki, Ioannis Papadopoulos, Loukas Settas, Dimitrios Zisopoulos, Fotini N. Skopouli, Alexios Iliopoulos, George K. Bertsias, Pierre Geborek, Alexandros A. Drosos, Dimitrios T. Boumpas & Prodromos Sidiropoulos, 2014, I : Seminars in Arthritis and Rheumatism. 43, 4, s. 447-457

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

  20. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

    Meliha C Kapetanovic, Lars Erik Kristensen, Tore Saxne, Teodora Aktas, Andreas Mörner & Pierre Geborek, 2014, I : Arthritis Research and Therapy. 16, 1, R2.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  21. Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort

    Lars Erik Kristensen, Henning Bliddal, Robin Christensen, Johan Karlsson, Anders Gülfe, Tore Saxne & Pierre Geborek, 2014, I : Arthritis Care and Research. 66, 2, s. 173-179

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  22. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort.

    Tor O Olofsson, Ingemar Petersson, Jonas Eriksson, Martin Englund, Julia F Simard, Jan-Åke Nilsson, Pierre Geborek, Lennart Jacobsson, Johan Askling & Martin Neovius, 2014, I : Annals of the Rheumatic Diseases. 73, 5, s. 845-853

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  23. 2013
  24. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.

    Johan Karlsson, Martin Neovius, Jan-Åke Nilsson, Ingemar Petersson, Johan Bratt, Ronald F van Vollenhoven, Sofia Ernestam & Pierre Geborek, 2013, I : Annals of the Rheumatic Diseases. 72, 12, s. 1927-1933

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  25. Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial

    Jonas K. Eriksson, Martin Neovius, Johan Bratt, Ingemar Petersson, Ronald F. van Vollenhoven, Pierre Geborek & Sofia Ernestam, 2013, I : JAMA Internal Medicine. 173, 15, s. 1407-1414

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  26. Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial

    Hamed Rezaei, Saedis Saevarsdottir, Pierre Geborek, Ingemar Petersson, Ronald F. van Vollenhoven & Kristina Forslind, 2013, I : BMC Musculoskeletal Disorders. 14, 79.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  27. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice

    Ingrid Lekander, Fredrik Borgstrom, Jorgen Lysholm, Ronald F. van Vollenhoven, Staffan Lindblad, Pierre Geborek & Gisela Kobelt, 2013, I : European Journal of Health Economics. 14, 6, s. 863-873

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  28. 2012
  29. A survey of spinal collateral actions of feline ventral spinocerebellar tract neurons.

    Pierre Geborek, Elisabeth Nilsson, F Bolzoni & E Jankowska, 2012, I : European Journal of Neuroscience.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  30. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

    Ronald F. van Vollenhoven, Pierre Geborek, Kristina Forslind, Kristina Albertsson, Sofia Ernestam, Ingemar Petersson, Katerina Chatzidionysiou & Johan Bratt, 2012, I : The Lancet. 379, 9827, s. 1712-1720

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  31. Decreased Neutrophil Apoptosis in Quiescent ANCA-Associated Systemic Vasculitis.

    Mohamed AbdGawad, Åsa Pettersson, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, Lars Nilsson, Mårten Segelmark & Thomas Hellmark, 2012, I : PLoS ONE. 7, 3, e32439.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  32. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

    Hamed Rezaei, Saedis Saevarsdottir, Kristina Forslind, Kristina Albertsson, Helena Wallin, Johan Bratt, Sofi Ernestam, Pierre Geborek, Ingemar Petersson & Ronald F. van Vollenhoven, 2012, I : Annals of the Rheumatic Diseases. 71, 2, s. 186-191

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  33. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment

    Kaisa Happonen, Tore Saxne, Pierre Geborek, Maria Andersson, Anders Bengtsson, Roger Hesselstrand, Dick Heinegård & Anna Blom, 2012, I : Arthritis Research and Therapy. 14, 1, R15.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  34. 2011
  35. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.

    Gisela Kobelt, Ingrid Lekander, Andrea Lang, Bernd Raffeiner, Costantino Botsios & Pierre Geborek, 2011, I : International Journal of Technology Assessment in Health Care. 27, 3, s. 193-200

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  36. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

    S. van Assen, N. Agmon-Levin, O. Elkayam, R. Cervera, M. F. Doran, M. Dougados, P. Emery, Pierre Geborek, J. P. A. Ioannidis, D. R. W. Jayne, C. G. M. Kallenberg, U. Mueller-Ladner, Y. Shoenfeld, L. Stojanovich, G. Valesini, N. M. Wulffraat & M. Bijl, 2011, I : Annals of the Rheumatic Diseases. 70, 3, s. 414-422

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  37. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

    M. Neovius, J. F. Simard, A. Sundstrom, L Jacobsson, Pierre Geborek, Tore Saxne, N. Feltelius, L. Klareskog & J. Askling, 2011, I : Annals of the Rheumatic Diseases. 70, 3, s. 516-519

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Föregående 1 2 3 Nästa